3D model is for representation purpose only.
.
.
![]() |
![]() |
![]() |
![]() |
![]() |
|---|---|---|---|---|
| RGDF | Estradiol-3-carboxymethyl ether |
| Identification | |
|---|---|
| ConjuPepDB ID | cpd01148 |
| Smiles | |
| Molecular weight | 847.412 |
| Molecular formula | C43H57N7O11 |
| Chemical name | Peptide information |
| Sequence (one letter) | RGDF |
| Length | 4 |
| Peptide name | tetrapeptide |
| External ID | |
|---|---|
| CAS number | 906673-88-9 |
| Other information | |
|---|---|
| Application | Osteoporosis therapy, estrogen replacement |
| Additional function | improved potency and reduced side effects |
| Pharmacological class | other |
| Conjugate type | amide |
| Linker | no |
| Small molecule | Estradiol-3-carboxymethyl ether |
| Small molecule CAS | 41164-36-7 |
| Structure method | 1H NMR |
| NMR solvent | DMSO-d13 |
| Calculated properties | |
|---|---|
| LogP | -0.53810 |
| Rotatable bonds | 21 |
| H bond donor | 10 |
| H bond acceptor | 13 |
| Polar surface area (PSA) | 299.43000 |
| Citations | |||||
|---|---|---|---|---|---|
| ID | Title | Year | Authors | Journal | DOI |
Improved anti-osteoporosis potency and reduced endometrial membrane hyperplasia during hormone replacement therapy with estrogen-RGD peptide conjugates | 2007 | Xiong, Yu; Zhao, Ming; Wang, Chao; Chang, Heng Wei; Peng, Shiqi | Journal of Medicinal Chemistry | ||